A new microemulsion formulation of cyclosporin (Neoral) is effective in the treatment of cyclosporin-resistant dermatoses
- 1 April 1996
- journal article
- case report
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 134 (4), 777-779
- https://doi.org/10.1111/j.1365-2133.1996.tb06990.x
Abstract
Summary Cyclosporin is a highly effective treatment for severe psoriasis and atopic dermatitis. However, both Inter‐ and intraparietal gastrointestinal absorption of the conventional formulation of cyclosporin (Sandeman) are very variable, ranging from 20 to 50%. Variations in bio availability may explain isolated resistance to therapy. Neoral is a novel microemulsion formulation of cyclosporin which has been developed to enhance and standardize its absorption. We report the first experience with Neoral in patients with psoriasis and atopic dermatitis refractory to Sandimmun.Keywords
This publication has 6 references indexed in Scilit:
- CYCLOSPORINE PHARMACOKINETICS AND VARIABILITY FROM A MICROEMULSION FORMULATION—A MULTICENTER INVESTIGATION IN KIDNEY TRANSPLANT PATIENTSTransplantation, 1994
- Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitisThe Lancet, 1991
- Long-term cyclosporin for psoriasisBritish Journal of Dermatology, 1989
- CYCLOSPORINE SUPPRESSION OF ENDOTHELIAL PROSTACYCLIN GENERATIONTransplantation, 1988
- LONG-TERM EFFECTS OF CYCLOSPORINS ON RENAL FUNCTION IN LIVER TRANSPLANT RECIPIENTSTransplantation, 1987
- CYCLOSPORIN A INITIALLY AS THE ONLY IMMUNOSUPPRESSANT IN 34 RECIPIENTS OF CADAVERIC ORGANS: 32 KIDNEYS, 2 PANCREASES, AND 2 LIVERSThe Lancet, 1979